Research programme: immunotherapies - Selecta Biosciences

Drug Profile

Research programme: immunotherapies - Selecta Biosciences

Latest Information Update: 25 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Developer Sanofi; Selecta Biosciences
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Coeliac disease; Food hypersensitivity

Most Recent Events

  • 06 Feb 2017 Preclinical trials in Coeliac disease in USA (Parenteral) before February 2017
  • 06 Feb 2017 Pharmacodynamics data from a preclinical study in Food allergy and Celiac disease presented at the GTCbio’s 5th Immunogenicity & Immunotoxicity Conference in San Diego, CA
  • 10 Nov 2016 Selecta Biosciences acquires rights for immunotherapies from Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top